Guidelines on Urolithiasis&lt;footref rid="foot01"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/footref&gt;

Tiselius, Hans‐Göran; Ackermann, Daniel; Alken, P.; Buck, Colin; Conort, Pierre; Gallucci, Michele

doi:10.1159/000049803

Cited by 502 publications

(128 citation statements)

References 593 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…We can also confirm that results from this trial were presented in poster form at the Confederation of American Urology (CAU) meeting in Chile (September [8][9][10][11]2010). …”

Section: Acknowledgmentssupporting

confidence: 83%

“…Current evidence suggests that, like opioids, nsNSAIDs are efficacious in controlling the signs and symptoms of renal colic (1); those drugs reduce urinary system distension and the associated pain through the inhibition of prostaglandins (10). As nsNSAIDs lack the addiction risk and known side effects of opioids, they may be the preferred treatment choice for the majority of patients with acute pain due to renal colic.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial

Glina¹,

Damião²,

Afif-Abdo³

et al. 2011

Int. braz j urol.

View full text Add to dashboard Cite

Purpose: Although nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and opioids are effective treatments for acute renal colic, they are associated with adverse events (AEs). As cyclooxygenase-2 selective NSAIDs may provide a safer alternative, we compared the efficacy and safety of parecoxib versus an nsNSAID in subjects with acute renal colic. Materials and Methods: Phase i.v., multicenter, double-blind, noninferiority, active-controlled study: 338 subjects with acute renal colic were randomized to parecoxib 40 mg i.v. plus placebo (n = 174) or ketoprofen 100 mg i.v. plus placebo (n = 164). 338 subjects with acute renal colic were randomized to parecoxib 40 mg i.v. (n = 174) or ketoprofen 100 mg i.v. (n = 164) plus placebo. Subjects were evaluated 15, 30, 45, 60, 90 and 120 minutes after treatment start and 24 hours after discharge. Primary endpoint was the mean pain intensity difference (PID) at 30 minutes by visual analog scale (VAS) (per-protocol population). An ANCOVA model was used with treatment group, country, and baseline score as covariates. Noninferiority of parecoxib to ketoprofen was declared if the lower bound of the 95% confidence interval (CI) for the difference between the two groups excluded the pre-established margin of 10 mm for the primary endpoint. Results: Baseline demographics were similar. The mean (SD) mPID30 min was 33.84 (24.61) and 35.16 (26.01) for parecoxib and ketoprofen, respectively. For treatment difference (parecoxib-ketoprofen) the lower bound of the 95% CI was 6.53. The mean change from baseline in VAS 30 minutes after study medication was ~43 mm; AEs were comparable between treatments.Conclusions: Parecoxib is as effective as ketoprofen in the treatment of pain due to acute renal colic, is well tolerated and has a comparable safety profile.

show abstract

“…We can also confirm that results from this trial were presented in poster form at the Confederation of American Urology (CAU) meeting in Chile (September [8][9][10][11]2010). …”

Section: Acknowledgmentssupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial

Glina¹,

Damião²,

Afif-Abdo³

et al. 2011

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…With close controls and in absence of risk factors like impaired renal function, pain, urinary tract infection or fever, these stones can be followed safely until spontaneously cleared. However, most authors recommend not exceeding 4-6 weeks, especially for obstructive ureteric calculi (14,15). These data show that the success rate is strongly influenced by the timing of therapeutic intervention (9).…”

Section: Commentsmentioning

confidence: 90%

Extracorporeal shockwave lithotripsy versus ureteroscopy for distal ureteric calculi: efficacy and patient satisfaction

2006

View full text Add to dashboard Cite

Objective: We compared the efficacy of extracorporeal shock wave lithotripsy (ESWL) and ureteroscopy (URS) for the treatment of distal ureteral calculi with respect to patient satisfaction. Materials and Methods: This is a prospective study where a total of 212 patients with solitary, radiopaque distal ureteral calculi were treated with ESWL (n = 92) using Dornier lithotriptor S (MedTech Europe GmbH) or URS (n = 120). Patient and stone characteristics, treatment parameters, clinical outcomes, and patient satisfaction were assessed for each group. Results: The 2 groups were comparable in regard to patient age, sex, stone size, and side of treatment. The stone-free status for ESWL and URS at 3 months was 81.5% and 97.5%, respectively (p < 0.0001). In addition, 88% of patients who underwent ESWL versus 20% who underwent URS were discharged home the day of procedure. Minor complications occurred in 3.3% and 8.3% of the ESWL and URS groups, respectively (p = 0.127). No ureteral perforation or stricture occurred in the URS group. Postoperative flank pain and dysuria were more severe in the URS than ESWL group, although the differences were not statistically significant (p = 0.16). Patient satisfaction was high for both groups, including 94% for URS and 80% for ESWL (p = 0.002). Conclusions: URS is more effective than ESWL for the treatment of distal ureteral calculi. ESWL was more often performed on an outpatient basis, and showed a trend towards less flank pain and dysuria, fewer complications and quicker convalescence. Patient satisfaction was significantly higher for URS according to the questionnaire used in this study.

show abstract

“…Extra-corporeal shockwave lithotripsy (ESWL) is the present mainstay of treatment for intra-renal and proximal ureteral stones ≤ 1cm in diameter due to its relatively low complication rate and high success rate (3,4). Current guidelines from American Association of Urology (AUA) recommend ESWL as the first treatment option for proximal ureteral calculi.…”

Section: Introductionmentioning

confidence: 99%

The S.T.O.N.E. Score: A new assessment tool to predict stone free rates in ureteroscopy from pre-operative radiological features

et al. 2014

View full text Add to dashboard Cite

show abstract

Guidelines on Urolithiasis<footref rid="foot01"><sup>1</sup></footref>

Cited by 502 publications

References 593 publications

Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial

Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial

Extracorporeal shockwave lithotripsy versus ureteroscopy for distal ureteric calculi: efficacy and patient satisfaction

The S.T.O.N.E. Score: A new assessment tool to predict stone free rates in ureteroscopy from pre-operative radiological features

Contact Info

Product

Resources

About